PROPHASE LABS INC. - COMMON STOCK
6.4700
28-March-24 15:58:00
15 minutes delayed
Stocks
+0.2100
+3.35%
Today's range
6.2273 - 6.5500
ISIN
N/A
Source
NASDAQ
-
ProPhase Labs Announces New $6 Million Stock Repurchase Program
15 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Data Presentation for its BE-Smart Esophageal Cancer Test
13 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
07 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
01 Mar 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Plans to Initiate Clinical Trial of Equivir (OTC)
22 Feb 2023 08:00:02 By Nasdaq GlobeNewswire
-
16 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
15 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
06 Feb 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
05 Jan 2023 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Acquires Rights to Novel Esophageal Cancer Test
19 Dec 2022 08:30:00 By Nasdaq GlobeNewswire
-
30 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Record Third Quarter 2022 Financial Results
10 Nov 2022 08:00:04 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute
08 Nov 2022 08:00:01 By Nasdaq GlobeNewswire
-
ProPhase Labs to Present at Investor Summit Group’s Q4 Conference
07 Nov 2022 19:12:00 By Nasdaq GlobeNewswire
-
04 Nov 2022 08:00:00 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Collaboration with G42 Healthcare
19 Oct 2022 08:00:02 By Nasdaq GlobeNewswire
-
ProPhase Labs to Present at The ThinkEquity Conference
18 Oct 2022 08:00:01 By Nasdaq GlobeNewswire
-
Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.
17 Oct 2022 08:00:01 By Nasdaq GlobeNewswire
-
06 Sep 2022 08:15:00 By Nasdaq GlobeNewswire
-
ProPhase Labs Announces Record Second Quarter 2022 Financial Results
11 Aug 2022 08:00:02 By Nasdaq GlobeNewswire